ASX Small and Mid-Cap Conference

10 September 2020

Disclaimer

The material contained in this presentation is intended to be general background information on Imricor Medical Systems Inc ("Imricor") and its activities.

The information is supplied in summary form and is therefore not necessarily complete. It is not intended that it be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs. The material contained in this presentation may include information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Unless otherwise noted, financial information in this presentation has been prepared in accordance with accounting principles generally accepted in the U.S. (US GAAP) and are denominated in US dollars.

This presentation may contain statements that constitute "forward-looking statements" within the meaning of Section 21E of the US Securities Exchange Act of 1934. Forward-looking statements are statements about matters that are not historical facts. Forward-looking statements appear in a number of places in this presentation and include statements regarding our intent, belief or current expectations with respect to our business and operations, market conditions, results of operations and financial condition.

We use words such as 'will', 'may', 'expect', 'intend', 'seek', 'would', 'should', 'could', 'continue', 'plan', 'estimate', 'anticipate', 'believe', 'probability', 'risk', 'aim', or other similar words to identify forward-looking statements. These forward-looking statements reflect our current views with respect to future events and are subject to change, certain risks, uncertainties and assumptions which are, in many instances, beyond our control, and have been made based upon management's expectations and beliefs concerning future developments and their potential effect upon us. There can be no assurance that future developments will be in accordance with our expectations or that the effect of future developments on us will be those anticipated. Actual results could differ materially from those which we expect, depending on the outcome of various factors. Factors that may impact on the forward-looking statements made include, but are not limited to, those described in the section titled 'Risk factors' in Imricor's prospectus dated 7 August 2019. When relying on forward-looking statements to make decisions with respect to us, investors and others should carefully consider such factors and other uncertainties and events. We are under no obligation to update any forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation.

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any other jurisdiction.

A pioneer and global leader in developing MRI-guided cardiac ablation products

Imricor is an innovative US based medical device company and is the only company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market

An overview of Imricor

Founder-led business with deep med-tech experience management team

The world's first commercially available MRI compatible catheter ablation devices

Strong IP portfolio and patent protection

Large addressable market, growing to over $4bn[1] by 2022, with favourable market drivers

Compelling value propositions for all stakeholders

Leveraging strategic relationships with Philips Healthcare and Siemens Healthineers

1. United States and Europe (comprises the UK, Germany, France, Spain and Italy)

Our journey to commercial launch in 2020 & plans for 2021

2006 • Imricor is established

2007 • Licensed IP from Johns Hopkins University

2008 • Received a grant from the US NIH

2014 • Performed first human pilot study with Active MR Tracking

2015 • Signed joint research agreement with Siemens Healthineers

2019 • Signed joint development agreement with Philips Healthcare

2020 • Received CE mark approval for Vision-MR Ablation Cather & Vision-MR Dispersive Electrode

• Commercial launch with first procedures outside clinical trial at Dresden Heart Centre

• Signed collaborative sales distribution agreement with Philips enabling Philips to sell Imricor's capital products

2006-2008 | 2009-2012 | 2013-2015 | 2016-2018 | 2018-2020 | 2021+

2009 • Developed technology for MRI compatibility

2011 • First in-man diagnostic and ablation procedures performed

2012 • First IP License revenue of Imricor IP to a third party

2016 • Received CE mark approval for the Advantage-MR EP Recorder/Stimulator

• Enrolled patients in clinical trial to support CE Mark approval for Vision-MR Ablation Catheter

2017 • Signed joint development agreement with Siemens Healthineers

• Awarded a contract with NIH to perform R&D on an MRI-compatible device for chemoablation

2018 • Signed first customer contract with Dresden Heart Centre

2021 plans

• Accelerate lab roll out plans
• Commercial release of diagnostic catheter
• Commence clinical trial to support FDA approval
• Commence clinical trial for expanded indications in the EU

Heart arrythmias and conventional treatment options

In the absence of MRI-compatible catheter ablation devices, physicians have been unable to take advantage of the potential benefits related to MRI guided ablation procedures for treating arrhythmias

Arrhythmias

- An arrhythmia is an abnormal heart rhythm
- Certain untreated arrhythmias can lead to serious cardiac conditions, such as blood clotting, stroke and/or death
- Rising global incidence of arrhythmias driven by secular demographic trends, such as aging population and increased occurrence of hypertension, obesity and diabetes

Conventional Treatment Options

- Conventional catheter ablation procedures performed guided by x-ray and aided by 3D mapping and tracking tools
- Antiarrhythmic drugs which focus on changing the electrical properties of cardiac tissue
- Implantable devices such as a pacemaker or defibrillator

The problems we are trying to solve through MRI guided ablation procedures

	Visualisation	Procedure effectiveness	Cost	Procedure time	Safety
Existing Challenges	• X-ray imaging provides poor heart visualisation • 3D mapping and tracking tools assist but have limitations • Inability to determine creation of permanent lesions	• Inability to determine permanency of lesions can negatively impact single procedures success rates which vary from 38% to over 95% depending on the type of arrythmia	• Repeat procedures can result in higher overall medical costs • A US study over a 5-year period showed medical costs for patients who require repeat AF ablations is 294% higher	• Conventional 3D mapping systems require additional time associated with image creation and calibration • Average procedure time for a conventional AFL ablation reported at 88 minutes	• Patient and doctor exposed to radiation during x-ray guided ablations • Occupational injuries can arise from heavy lead protective garments worn by medical professionals
Imricor's Solution	• Soft tissue of the heart is clearly visible in real-time • Both 2D and 3D imaging available • Non-permanent lesions can be identified during the procedures and filled	• Reduced likelihood of a repeat procedure due to ability to determine permanency of lesions • Imricor's clinical trial delivered a 100% chronic success rate for AFL procedures	• Per-procedure cost comparable to the cost of a conventional x-ray guided procedure • Increased effectiveness, fewer procedures and lower overall treatment cost	• Physician inserts catheter and commences procedure immediately • Average procedure time for MRI-guided AFL ablations is 48 minutes • Faster procedure times could enable more procedures	• MRI generates no radiation and eliminates risk of radiation injury • Physicians do not need to wear heavy protective garments

Partnering to deliver success and drive growth

Imricor has entered into a number of agreements with market leading organisations to support future iCMR lab adoption

PHILIPS

- Joint development agreement to establish compatibility between Imricor's products and Philips mapping software
- Non-exclusive collaborative sales distribution agreement for Imricor's capital products

Opto acoustics

- Faciliates the introduction of a market leading communications solution for MRI applications

SIEMENS Healthineers

- Joint development agreement to establish compatibility between Imricor's products and Siemens mapping software

Herzzentrum Dresden UniversitätsKlinik an der Technischen Universität Dresden

- Training Centre of Excellence on Siemens platform

Leipzig Heart Center

- Training Centre of Excellence on Philips platform

Sana Einkauf & Logistik

- Imricor products included in approved catalogue, establishing pricing and eliminating contract negotiations

MiRTLE

- Joint development agreement to integrate 12-lead ECG system with Imricor's products

The product portfolio

Consumable Products

Vision-MR Ablation Catheter

Vision-MR Dispersive Electrode



- Received CE mark approval in January 2020
- Ablation catheter CE mark approval with an indication for treating type 1 atrial flutter
- Imricor is the exclusive provider

Capital Product

Advantage-MR EP Recorder / Stimulator

- Received CE mark approval in January 2016
- Under collaborative sales distribution agreement, can be sold as part of a Philips comprehensive iCMR installation package

Pipeline products under development

Consumable Products

Diagnostic Catheter



- Aiming for mid-2021 commercial release (pending approval)
- Supporting margin improvements

Steerable Sheath and Transeptal Needle



- Currently in prototype phase
- Aiming to be ready for clinical trials in 2021
- Supporting expanded indications

A strong intellectual property portfolio



- Imricor's IP is relatively new, with the Company's oldest issued patent expiring in 2030
- In addition to protecting Imricor's devices and procedures, its patents provide an opportunity for the Company to license its technology to 3rd party medical device companies (particularly implant manufacturers) to help make their devices compatible with MRI
- To date, Imricor has executed 3 separate agreements where it has licensed its own patents to 3rd parties for use in implantable devices under which Imricor has received over US$13m of payments to date

Our business model

Today Imricor primarily generates revenue from the sale of its capital equipment and consumable products



A strong and growing market in cardiac ablation

A large global addressable market with high growth potential supported by favourable growth drivers

Drivers of Global Catheter Ablation Market

- Increased incidence of cardiac disease
- Shift towards minimally invasive procedures
- Cost effectiveness of catheter ablation as treatment option

EU[1] and US Cardiac Ablation Market



Sources:
Millennium Research Group *Electrophysiology Mapping and Ablation Devices Europe 2021* July 2020
Millennium Research Group *Electrophysiology Mapping and Ablation Devices US 2021* June 2020

1. EU represented by five countries: UK, Germany, France, Spain, Italy

Core strategies to drive future growth

Imricor's strategy is focused on the two drivers that are key to revenue growth – the number of iCMR labs and the number of procedures performed using Imricor's consumables in each lab

Go to market strategies

- Collaborative sales distribution agreement with Philips
- Strategic relationship with Siemens
- Growing awareness through sales and marketing activities
- Engagement with Key Opinion Leaders
- Comprehensive training and support at clinical sites

Geographic expansion

- CE mark approval enables the sale of products in the EU
- Strategy to obtain FDA approval in the US well advanced and targeting clinical trials in 2021-2022
- Local agent to be selected to support TGA approval in Australia

Expanded indications



- Ablation catheter has CE mark approval for the treatment of atrial flutter
- Atrial flutter comprises only 23% of ablation procedures in the EU
- Planning to commence clinical trials to expand CE mark approval to other indications in 2021

Future acceleration in lab rollout plans underpinned by strong pipeline

3 sites operational

- Dresden: Commenced routine procedures in January 2020, training Centre of Excellence
- Haga: Commenced routine procedures in June 2020
- UMC Ams: Commenced routine procedures in June 2020

5 sites with agreements in final stages

- Includes Leipzig Heart Centre to be established as a training Centre of Excellence
- MR labs currently in place
- Installation, training and start-up dates scheduled or being scheduled
- Signing of contracts and/or commencement of procedures expected within next 4-6 weeks[1]

14 sites with well-progressed discussions

- Well progressed and in the third stage of Imricor's 5 stage sales process
- Supporting acceleration in lab roll out during Q4 2020[1]

Strong pipeline

- Strong and growing pipeline of potential sites supported by increasing awareness and education of Imricor's product
- Agreement with Sana GPO provides access to ~80 sites for sales & marketing
- Further enhanced by Philips sales distribution agreement to drive lab adoption

Initial sites (e.g. Dresden, Leipzig) are set up as training Centres of Excellence for sites that follow

1. Assuming no further COVID-19 related disruptions

Pipeline growth supported by early clinical success

Early clinical success and excellent physician feedback is driving growing interest in Imricor's products and the opportunity to establish a new standard of care in the treatment of heart arrythmias, with particular focus on expanded indications

"This is beautiful. It is better than fluoroscopy. In fluoroscopy you can only imagine the anatomy. Here you see it" – Dr Christopher Piorowski, Dresden Heart Centre

"Performing this procedure under MRI allows for direct peri-procedure visualization of ablation lesions. This has the potential to improve clinical results substantially" – Dr. Marco Gotte, Amsterdam University Medical Centre

"In all respect, this is a major step forward for patients with cardiac arrhythmias and also for hospitals" – Dr. Ivo van der Bilt, Haga Hospital

Our focus for the year ahead

Imricor's focus for the balance of 2020 is on continuing to execute a controlled product launch throughout the EU while pursuing growth opportunities that position the company strongly into 2021 and onwards

- Continued lab roll out with focus on acceleration in the last quarter of 2020
- Training of Philips sales force to drive the pipeline of iCMR labs
- Ongoing development of lab pipeline through Imricor's marketing activities and collaboration with Siemens
- R&D focus on product pipeline required for expanding indications and margin improvements
- Continue with regulatory approvals to expand into Australia and the US
- Strategy around clinical trials for new products and expanding indications
- GM improvement initiatives to deliver benefits in future years



Q&A


ADVANTAGE-MR
Digital Amplifier Stimulator
ABL CATH
CATH 2
TEMP
imricor

What to learn more about Imricor?

Transforming Cardiac Ablation Procedures

Imricor corporate procedural video

https://vimeo.com/438663377

Experience the Future of Cardiac Ablation

Dr. Thomas Gaspar and Dr. Stefan Ulbrich from the Dresden Heart Centre discuss their successes performing cardiac ablation utilising real-time MR imaging

https://www.youtube.com/watch?v=qjXiMWuuvDI

Early Results and Experiences for iCMR in Atrial Flutter

Jakob Tomala, Heart Centre Dresden

Ablation Center of the Future

Ivo Van Der Bilt, Haga Hospital

https://www.magnetomworld.siemens-healthineers.com/magnetom-world-summit/recordings

SIEMENS Healthineers

Contact information

Investors:

Steve Wedan
Executive Chair, President & CEO
Email: steve.wedan@imricor.com

Carrie Barrack
Cato & Clive
Email: carrie@catoandclive.com

Website:

https://imricor.com/

Follow us: